Can I stop using spaxentan after taking it? Patient FAQs

Sparsentan is a new type of targeted drug, mainly used to treat chronic kidney disease caused by proteinuria, especially in the treatment of specific types of kidney disease (such as FSGS). Sparsentane slows the progression of kidney disease by inhibiting both endothelinA receptors and angiotensinII receptors. However, whether patients can stop taking sparsentane is an issue that needs to be approached with caution.

The therapeutic effects of sparsentane usually require long-term maintenance. While taking sparsentane, the drug helps patients manage their condition by improving kidney function, reducing proteinuria, and slowing the progression of kidney disease. If the patient stops taking the medication without authorization, the condition may relapse or worsen. Especially in the early stages of chronic kidney disease, stopping the medication may cause the disease to progress rapidly. Therefore, doctors usually recommend that patients gradually adjust drug dosage or make discontinuation decisions under the guidance of a doctor.

The decision to discontinue treatment should be based on the patient's specific condition and response to treatment. If the patient's condition is stable while taking sparsentan and the proteinuria level decreases significantly, a gradual dose reduction or discontinuation can be considered under the supervision of a doctor. However, even if symptoms resolve, kidney function and proteinuria levels still need to be checked regularly to ensure the disease does not return. Sudden discontinuation of medication may cause the medication to lose its effectiveness, causing the condition to relapse.

Patients should avoid stopping medication or adjusting their medication regimen on their own. Discontinuation of any drug should be done under the advice of a physician, who will evaluate the patient based on factors such as the patient's condition, drug response, and renal function. For most patients with chronic kidney disease, sparsentane may need to be used as part of long-term management, and changes in the condition need to be closely monitored after the drug is discontinued to ensure that kidney function does not worsen. Therefore, during the treatment process, patients should maintain close communication with their doctors to jointly develop the most appropriate treatment plan.

Reference materials:https://www.sparsentan.com/